The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation

Pang, Bo; Zhang, Lulu; Li, Bin; Sun, Feng-Xian; Wang, Zhida

doi:10.1016/j.physbeh.2023.114134

Cited by 4 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that in an AD-T1DM mouse model, engeletin reduced neuronal loss, decreased senile plaque load, and ameliorated cognitive deficits in mice [41] . In the STZ-ICV-injected rat model, engeletin was found to ameliorate cognitive deficits and inhibit hippocampal AChE activity, which may be related to the inhibition of tau hyperphosphorylation induced by disruption of insulin signaling [42] . Recent studies explored the molecular interactions of human brain AChE with these antidiabetic drugs and suggested that canagliflozin and Dapagliflozin may have an inhibitory effect on AChE [43] .…”

Section: Sodium-glucose Cotransporter (Sglt-2) Inhibitorsmentioning

confidence: 97%

New advances in the treatment of Alzheimer's disease with antidiabetic drugs

2023

IJFM

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a persistent neurological disorder characterized by increasing cognitive impairment and is the most prevalent type of dementia. The most common pathological features are amyloid plaques due to amyloid-β (Aβ) deposits and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau proteins that accumulate abnormally in the brain. Nearly a decade of clinical studies and preclinical data have demonstrated that AD shares common pathologic mechanisms with type 2 diabetes mellitus (T2DM), including insulin resistance, oxidative stress, and inflammatory responses. Since they share a common pathological mechanism and AD lacks an effective treatment, it is of great clinical significance to investigate whether AD can be treated with existing T2DM drugs.

show abstract

Section: Sodium-glucose Cotransporter (Sglt-2) Inhibitorsmentioning

confidence: 97%

New advances in the treatment of Alzheimer's disease with antidiabetic drugs

2023

IJFM

View full text Add to dashboard Cite

show abstract

Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges

Tran,

Parekh,

Rockcole

et al. 2024

Life Sciences

View full text Add to dashboard Cite

SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system

Mei,

Li,

Niu

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, are increasingly studied for their cognitive benefits. These benefits may include reduction of oxidative stress and neuroinflammation, decrease of amyloid burdens, enhancement of neuronal plasticity, and improved cerebral glucose utilization. The multifaceted effects and the relatively favorable side-effect profile of SGLT2 inhibitors render them a promising therapeutic candidate for cognitive disorders. Nonetheless, the application of SGLT2 inhibitors for cognitive impairment is not without its limitations, necessitating more comprehensive research to fully determine their therapeutic potential for cognitive treatment. In this review, we discuss the role of SGLT2 in neural function, elucidate the diabetes-cognition nexus, and synthesize current knowledge on the cognitive effects of SGLT2 inhibitors based on animal studies and clinical evidence. Research gaps are proposed to spur further investigation.

show abstract

The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation

Cited by 4 publications

References 51 publications

New advances in the treatment of Alzheimer's disease with antidiabetic drugs

New advances in the treatment of Alzheimer's disease with antidiabetic drugs

Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges

SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system

Contact Info

Product

Resources

About